Prognostic value of different factors in breast carcinoma

Tumori

Volumn 90, Issue 1, 2004, Pages 112-119

  Hlupić, Ljiljana ^a,b   Jakić Razumović, Jasminka ^a   Božikov, Jadranka ^a   Ćorić, Marijana ^a   Belev, Borislav ^a   Vrbanec, Damir ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

bcl 2; Breast carcinoma; c erbB 2; Immunohistochemistry; Ki 67; Lymph node status; nm23; Nottingham prognostic index; p53; Prognostic factors; Steroid receptors; Survival analysis

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; GENE PRODUCT; HORMONE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STAINING; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 2142709552     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000123     Document Type: Article

References (54)

1. Le MG, Arriagada R, Spielmann M, Guinebretiere JM, Rochard F: Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer, 94: 2813-2820, 2002.
2. Lash TL, Silliman RA, Guadagnoli E, Mor V: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer, 89: 1739-1747, 2000.
3. Sierra A, Castellsague X, Escobedo A, Lloveras B, Garcia-Ramirez M, Moreno A, Fabra A: Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer, 89: 142-147, 2000.
4. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res, 49: 6675-6679, 1989.
5. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J: C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol, 12: 525-533, 2001.
6. Thike AA, Chng MJ, Fook-Chong S, Tan PH: Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology, 33: 21-25, 2001.
7. Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, Hughes K: Predicting the survival of patients with breast carcinoma using tumor size. Cancer, 95: 713-723, 2002.
8. Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg, 235: 10-26, 2002.
9. Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK: Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer, 89: 2521-2526, 2000.
10. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer, 82: 1296-1302, 1998.
11. Hartveit F: Node-positive breast cancer: axillary micrometastases, their incidence and some implications. Invasion Metastasis, 16: 317-321, 1996.
12. Bisho McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst, 83: 154-155, 1991.
13. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH: Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 15: 853-861, 2002.
14. Watatani M, Inui H, Nagayama K, Imanishi Y, Nishimura K, Hashimoto Y, Yamauchi E, Hojo T, Kotsuma Y, Yamato M, Matsunami N, Yasutomi M: Identification of high-risk breast cancer patients from genetic changes of their tumors. Surg Today, 30: 516-522, 2000.
15. Johnston J: Human genetic disorders. J NIH Res, 4: 153, 1992.
16. Benz EJ: The molecular genetics of cancer: introduction to principles of recombinant DNA technology. Cancer, 65: 731, 1990.
17. Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC, Seidman JG, Smith DR (Eds): Current protocols in human genetics. John Wiley & Sons, New York, 1994.
18. Delides GS, Garas G, Georgouli G Jiortziotis D, Lecca J, Liva T, Elemenglou J: Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med, 106: 126-128, 1982.
19. Gasparini G, Pozza F, Harris AL: Methodology of evaluation and potential usefulness of the new biological-related prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst, 85: 1206-1219, 1993.
20. Kinne DW: Staging and follow-up of breast cancer patients. Cancer, 67: 1196-1198, 1991.
21. World Health Organisation: Histological typing of breast tumors. Tumori, 68: 181-198, 1982.
22. rd ed, Churchill Livingstone, London, 1998.
23. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham prognostic index in primary breast cancer. Br Cancer Res Treat, 22: 207-219, 1992.
24. Matsuo K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Tsuda H: Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer, 9: 127-133, 2002.
25. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvantis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix component tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer, 38: 2362-2370, 2002.
26. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. Am Stat Assoc J, 53: 457-481, 1958.
27. Cox DR: Regression models and life tables. J R Stat Soc, 84: 1035-1044, 1972.
28. Devi KR, Kuruvila S, Musa MM: Pathological prognostic factors in breast carcinoma. Saudi Med J, 21: 372-375, 2000.
29. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63: 181-186, 1989.
30. Medina-Franco H, Urist MM: Occult breast carcinoma presenting with axillary lymph node metastases. Rev Invest Clin, 54: 204-208, 2002.
31. Millis RR, Springall RJ, Hanby AM, Ryder K, Fentiman IS: A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer, 88: 108-113, 2000.
32. Menard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol, 19: 329-335, 2001.
33. Crombie N, Rampaul RS, Pinder SE, Elston CW, Robertson JF, Ellis IO: Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. Br J Surg, 88: 1324-1329, 2001.
34. Keshtgar MR, Baum M: Axillary dissection over the years: where to from here? World J Surg, 25: 761-766, 2001.
35. Lash TL, Silliman RA, Guadagnoli E, Mor V: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer, 89: 1739-1747, 2000.
36. Clark J, Edwards S, John M, Flohr P, Gordon T, Maillard K, Giddings I, Brown C, Bagherzadeh A, Campbell C, Shipley J, Wooster R, Cooper CS: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer, 34: 104-114, 2002.
37. Ho GH, Calvano JE, Bisogna M, Abouezzi Z, Borgen PI, Cordon-Cardo C, van Zee KJ: Genetic alterations of the p14ARF-hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res Treat, 65: 225-232, 2001.
38. Thomson AM, Steel CM, Chetty U, Carter DC: Evidence for the multistep theory of carcinogenesis in human breast carcinoma. Breast, 1: 29, 1992.
39. Bishop JM: The molecular genetics of cancer. Science, 235: 305, 1987.
40. Bishop JM: Molecular themes in oncogenesis. Cell, 64: 235, 1991.
41. Schwab M, Amler LC: Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer, 1: 181, 1990.
42. Lee EY-HP: Tumor suppressor genes: a new era for molecular genetic studies of cancer. Breast Cancer Res Treat, 19: 3, 1991.
43. Marchall CJ: Tumor suppressor genes. Cell, 64: 313, 1991.
44. Montero S, Guzman C, Vargas C, Ballestin C, Cortes-Funes H, Colomer R: Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol, 22: 337-344, 2001.
45. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S: Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res, 99: 161-168, 2001.
46. Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res, 17: 3091-3097, 1997.
47. Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer, 74: 229-233, 1996.
48. El-Ahmady O, El-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A: Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. Anticancer Res, 22: 2493-2499, 2002.
49. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88: 804-813, 2000.
50. Raabe NK, Hagen S, Haug E, Fossaa SD: Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma. Int J Oncol, 12: 1091-1096, 1998.
51. Gohring UJ, Scharl A, Heckel C, Ahr A, Crombach G: P53 protein in 204 patients with primary breast carcinoma: immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet, 256: 139-146, 1995.
52. Katakura H, Tanaka F, Oyanagi H, Miyahara R, Yanagihara K, Otake Y, Wada H: Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer. Ann Thorac Surg, 73: 1060-1064, 2002.
53. Niu Y, Fu X, Lv A, Fan Y, Wang Y: Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer, 98: 754-760, 2002.
54. Sauer T, Furu I, Beraki K, Jebsen PW, Ormerod E, Naess O: Nm23 protein expression in fine-needle aspirates from breast carcinoma: inverse correlation with cytologic grading, lymph node status, and ploidy. Cancer, 84: 109-114, 1998.